Aktis Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKTS research report →
Range $35 – $40
Price Chart
About the company
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes.
- CEO
- Matthew Roden
- IPO
- 2026
- Employees
- 79
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on AKTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $997.28M
- P/E
- -17.82
- PEG
- 0.17
- P/S
- 99.32
- P/B
- 2.13
- EV/EBITDA
- -11.94
- Div Yield
- 0.00%
- Gross Margin
- 84.78%
- Op Margin
- -866.63%
- Net Margin
- -727.04%
- ROE
- -41.07%
- ROIC
- -16.54%
Latest fiscal year · YoY change
- Revenue
- $6.50M+336.9%
- Gross Profit
- $6.50M+336.9%
- Op Income
- $-74,684,000
- Net Income
- $-63,731,000-44.9%
- EPS
- $-1.19+5.6%
- OCF Growth
- -534.4%
- FCF Growth
- -719.4%
- 52W High
- $34.19
- 52W Low
- $14.72
- 50D MA
- $23.27
- 200D MA
- $21.48
- Beta
- 0.45
- RSI (14)
- 29
- Avg Volume
- 373.75K
No earnings-call transcripts are available for AKTS yet.
- Free Float
- 0.9%
- Shares Outstanding
- 53.40M
- Float Shares
- 483.13K
of shares held by institutions
116 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bioimpact Capital LLC | 4.84M | 0 |
| Ecor1 Capital, LLC | 4.82M | 0 |
| Blue Owl Capital Holdings LP | 3.07M | ▼ 91.13K |
| Blackrock, Inc. | 2.28M | ▲ 166.23K |
| T. Rowe Price Investment Management, Inc. | 2.05M | ▼ 72.36K |
| Wellington Management Group Llp | 1.97M | ▼ 350.80K |
| Rtw Investments, LP | 1.59M | 0 |
| Janus Henderson Group Ltd. | 1.45M | ▲ 1.45M |
| Ra Capital Management, L.P. | 1.31M | ▼ 188.68K |
| Jupiter Topco LLC | 1.31M | ▲ 1.31M |
| Baker Bros. Advisors LP | 996.35K | 0 |
| Octagon Capital Advisors LP | 960.85K | 0 |
Held by 132 ETFs
Biggest fund positions in AKTS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | Czibere Akos | other | 12,500 |
| Sep 23, 26 | Czibere Akos | other | 12,500 |
| Sep 23, 26 | Czibere Akos | sell | 5,099 |
| Sep 23, 26 | Czibere Akos | sell | 7,401 |
| Jan 12, 26 | ELI LILLY & Co | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AKTS coverage
Recent articles, reports, and earnings notes.
No research on AKTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AKTS report →Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
globenewswire.com · Oct 1
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
investopedia.com · Aug 14
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
globenewswire.com · Aug 13
Aktis Oncology: Mini-Proteins With A Targeted Punch
seekingalpha.com · Jun 11
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
globenewswire.com · May 27
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
globenewswire.com · May 21
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
fool.com · May 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.